MARKET

RGNX

RGNX

Regenxbio
NASDAQ
12.21
+0.57
+4.90%
Closed 16:23 06/18 EDT
OPEN
11.77
PREV CLOSE
11.64
HIGH
12.28
LOW
11.62
VOLUME
860.33K
TURNOVER
0
52 WEEK HIGH
28.80
52 WEEK LOW
11.56
MARKET CAP
601.42M
P/E (TTM)
-2.0775
1D
5D
1M
3M
1Y
5Y
RegenXBio Poised for Success with Innovative Gene Therapy RGX-121: A Buy Rating Analysis
TipRanks · 1d ago
Regenxbio Concludes Pre-biologics License Application Meeting For RGX-121 For Mucopolysaccharidosis Type II, Where It Finalized Details Of Its Application With The FDA, Expects To Initiate Submission Of A Rolling BLA In Q3 Of 2024
Aligned with FDA on content of BLA and plans for submission. Submission of a rolling BLA expected to start in Q3 2024. FDA confirmed RGX-121 commercial bulk drug is comparable to clinical material. The drug is expected to undergo a confirmatory trial in 2025.
Benzinga · 2d ago
REGENXBIO INC: A CONFIRMATORY STUDY OF RGX-121 IS EXPECTED TO INITIATE ENROLLMENT IN SECOND HALF OF 2025
Reuters · 2d ago
Weekly Report: what happened at RGNX last week (0610-0614)?
Weekly Report · 3d ago
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
NASDAQ · 3d ago
Shareholders in REGENXBIO (NASDAQ:RGNX) have lost 77%, as stock drops 12% this past week
RegenXBIO Inc. (NASDAQ:RGNX) has lost 38% in the last year. The share price of the company has fallen 12% per year over the last five years. The company didn't make a profit in the past 12 months. The stock has also lost 44% in last 90 days. We look at the company's fundamentals to see what we can learn from its performance.
Simply Wall St · 5d ago
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
MarketWatch · 06/13 12:49
RegenXBio Announces Leadership Shuffle and Financial Outlook
TipRanks · 06/13 11:51
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.